Recent Updates
Recently added Catalysts
XNCR Positive Sentiment

Xencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Xencor, Inc. presented initial dose-escalation data for plamotamab at ACR Convergence 2026. This bispecific T-cell engager targets CD20 and CD3 in adults with rheumatoid arthritis. The ongoing Phase 1b study aims to assess its safety and efficacy, marking a significant step in Xencor's research efforts.

Market Sentiment Analysis

POSITIVE FACTORS

  • Initial data shows promise for plamotamab in rheumatoid arthritis.
  • Xencor is advancing its Phase 1b study effectively.
  • Presentation at ACR Convergence 2026 highlights research progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+243%
120-day peak, hindsight
Typical move
12.8%
average across 4 past catalysts
Lead asset
XmAb13676
Phase 1 · B-cell Non-Hodgkins Lymphoma

Full Press Release Details

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data are being presented in a poster session at the American College of Rheumatology (ACR) Convergence 2026 conference in

Frequently Asked Questions

What is plamotamab?

Plamotamab is a bispecific CD20 x CD3 T-cell engager developed by Xencor.

What disease is plamotamab targeting?

Plamotamab targets rheumatoid arthritis in adults.

Where was the data presented?

The data was presented at the ACR Convergence 2026 conference.

What phase is the plamotamab study in?

The study is currently in Phase 1b.

ShareAdd on Google
Tags: XNCR Xencor plamotamab rheumatoid arthritis Phase 1b ACR Convergence
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$556M liquidity · $0M/mo burn
Low dilution risk
Lead asset
XmAb13676Phase 1
B-cell Non-Hodgkins Lymphoma →

Catalyst track record

+243%
best trade around XNCR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for XNCR.

See every catalyst's timing & PoA →